Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? - PubMed (original) (raw)
doi: 10.1038/sj.mp.4002133. Epub 2008 Jan 15.
F M Theisen, M Haberhausen, M B Raeder, J Fernø, S Gebhardt, A Hinney, H Remschmidt, J C Krieg, C Mehler-Wex, M M Nöthen, J Hebebrand, V M Steen
Affiliations
- PMID: 18195716
- DOI: 10.1038/sj.mp.4002133
Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
S Le Hellard et al. Mol Psychiatry. 2009 Mar.
Abstract
Atypical antipsychotics are nowadays the most widely used drugs to treat schizophrenia and other psychosis. Unfortunately, some of them can cause major metabolic adverse effects, such as weight gain, dyslipidemia and type 2 diabetes. The underlying lipogenic mechanisms of the antipsychotic drugs are not known, but several studies have focused on a central effect in the hypothalamic control of appetite regulation and energy expenditure. In a functional convergent genomic approach we recently used a cellular model and demonstrated that orexigenic antipsychotics that induce weight gain activate the expression of lipid biosynthesis genes controlled by the sterol regulatory element-binding protein (SREBP) transcription factors. We therefore hypothesized that the major genes involved in the SREBP activation of fatty acids and cholesterol production (SREBF1, SREBF2, SCAP, INSIG1 and INSIG2) would be strong candidate genes for interindividual variation in drug-induced weight gain. We genotyped a total of 44 HapMap-selected tagging single nucleotide polymorphisms in a sample of 160 German patients with schizophrenia that had been monitored with respect to changes in body mass index during antipsychotic drug treatment. We found a strong association (P=0.0003-0.00007) between three markers localized within or near the INSIG2 gene (rs17587100, rs10490624 and rs17047764) and antipsychotic-related weight gain. Our finding is supported by the recent involvement of the INSIG2 gene in obesity in the general population and implicates SREBP-controlled lipogenesis in drug-induced metabolic adverse effects.
Similar articles
- Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples.
Le Hellard S, Mühleisen TW, Djurovic S, Fernø J, Ouriaghi Z, Mattheisen M, Vasilescu C, Raeder MB, Hansen T, Strohmaier J, Georgi A, Brockschmidt FF, Melle I, Nenadic I, Sauer H, Rietschel M, Nöthen MM, Werge T, Andreassen OA, Cichon S, Steen VM. Le Hellard S, et al. Mol Psychiatry. 2010 May;15(5):463-72. doi: 10.1038/mp.2008.110. Epub 2008 Oct 21. Mol Psychiatry. 2010. PMID: 18936756 - Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.
Opgen-Rhein C, Brandl EJ, Müller DJ, Neuhaus AH, Tiwari AK, Sander T, Dettling M. Opgen-Rhein C, et al. Pharmacogenomics. 2010 Jun;11(6):773-80. doi: 10.2217/pgs.10.50. Pharmacogenomics. 2010. PMID: 20504252 - Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs.
Fernø J, Skrede S, Vik-Mo AO, Håvik B, Steen VM. Fernø J, et al. BMC Neurosci. 2006 Oct 20;7:69. doi: 10.1186/1471-2202-7-69. BMC Neurosci. 2006. PMID: 17052361 Free PMC article. - Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Basile VS, et al. J Clin Psychiatry. 2001;62 Suppl 23:45-66. J Clin Psychiatry. 2001. PMID: 11603885 Review. - Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T, Kin NM, Beaulieu S, de Baptista EA. Baptista T, et al. Pharmacopsychiatry. 2002 Nov;35(6):205-19. doi: 10.1055/s-2002-36391. Pharmacopsychiatry. 2002. PMID: 12518268 Review.
Cited by
- Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis.
Zhou X, Shin S, He C, Zhang Q, Rasband MN, Ren J, Dai C, Zorrilla-Veloz RI, Shingu T, Yuan L, Wang Y, Chen Y, Lan F, Hu J. Zhou X, et al. Elife. 2021 May 4;10:e60467. doi: 10.7554/eLife.60467. Elife. 2021. PMID: 33942715 Free PMC article. - Etiology of cardiovascular disease in patients with schizophrenia: current perspectives.
Emul M, Kalelioglu T. Emul M, et al. Neuropsychiatr Dis Treat. 2015 Oct 1;11:2493-503. doi: 10.2147/NDT.S50006. eCollection 2015. Neuropsychiatr Dis Treat. 2015. PMID: 26491327 Free PMC article. Review. - Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.
Suvitaival T, Mantere O, Kieseppä T, Mattila I, Pöhö P, Hyötyläinen T, Suvisaari J, Orešič M. Suvitaival T, et al. Transl Psychiatry. 2016 Nov 15;6(11):e951. doi: 10.1038/tp.2016.222. Transl Psychiatry. 2016. PMID: 27845774 Free PMC article. - Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain.
Panizzutti B, Bortolasci CC, Spolding B, Kidnapillai S, Connor T, Richardson MF, Truong TTT, Liu ZSJ, Gray L, Kim JH, Dean OM, Berk M, Walder K. Panizzutti B, et al. J Clin Med. 2021 Sep 10;10(18):4095. doi: 10.3390/jcm10184095. J Clin Med. 2021. PMID: 34575210 Free PMC article. - The promise and reality of pharmacogenetics in psychiatry.
Zandi PP, Judy JT. Zandi PP, et al. Psychiatr Clin North Am. 2010 Mar;33(1):181-224. doi: 10.1016/j.psc.2009.12.001. Psychiatr Clin North Am. 2010. PMID: 20159346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases